Under construction – not a live service
Sign in

2022-502997-18-00CompletedPhase 1

Single-dose Study of BMS-986326 at Two Dose Levels in Participants with Atopic Dermatitis

Source: EU CTIS (euclinicaltrials.eu) · Last updated 5 Nov 2025

Next steps

Status (registry)
Completed
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
64 (actual)
First submitted
18 May 2023
Start date
2 Feb 2024
Lead sponsor
Bristol-Myers Squibb Services Unlimited Company
EU CT number
2022-502997-18-00

What you commit to

  • Study type: Interventional · Phase 1
  • Participants enrolled: 64
  • 17 sites in 5 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

Sites (17)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Pratia Pardubice a.s.Pardubice ICzechiaCompleted
Clintrial s.r.o.Prague 10CzechiaCompleted
Charite Research Organisation GmbHBerlinGermanyCompleted
Gesundheit Nord gGmbH Klinikverbund BremenBremenGermanyCompleted
Deutsches Rotes Kreuz Gemeinnuetzige Krankenhaus GmbH SachsenChemnitzGermanyCompleted
Staedtisches Klinikum DessauDessau-RosslauGermanyCompleted
Universitaetsklinikum Heidelberg AöRHeidelbergGermanyCompleted
University Medical Centre Schleswig-HolsteinLübeckGermanyCompleted
Hospital Universitario Reina SofiaCórdobaSpainCompleted
Hospital Universitario de Gran Canaria Dr NegrínLas Palmas de Gran CanariaSpainCompleted
University Hospital Of Clermont-FerrandClermont-FerrandFranceCompleted
Centre Hospitalier Universitaire de NiceNiceFranceCompleted
Hospices Civils de LyonPierre-BéniteFranceCompleted
Malopolskie Centrum KliniczneCracowPolandCompleted
Pratia S.A.KatowicePolandCompleted
Uniwersytecki Szpital Kliniczny Im. Fryderyka Chopina W RzeszowieRzeszówPolandCompleted
WroMedica I Bielicka A Strzalkowska s cWroclawPolandCompleted

Are you the coordinator? Confirm the details

This page is information, not medical advice. Discuss any trial with your doctor.